{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T21:04:47Z","timestamp":1781557487535,"version":"3.54.5"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background<\/jats:bold>: The information is relatively scarce regarding the occurrence of drug-induced acute kidney injury (AKI) when anti-coronavirus disease 2019 (COVID-19) drugs are prescribed for patients with diabetes mellitus (DM).<\/jats:p><jats:p><jats:bold>Objective<\/jats:bold>: The objective of this study was to evaluate a pharmacovigilance signal for AKI upon the use of common drugs prescribed for COVID-19 treatment, especially in patients with DM.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold>: The FDA Adverse Event Reporting System (FAERS) database were used, and data from the first quarter of 2020 to the third quarter of 2021 were retrieved. A disproportionality analysis was performed to determine whether AKI was more frequently reported with anti-COVID-19 drugs compared to that with other drugs in different populations. Further, reporting odds ratios (RORs) and their 95% confidence intervals (CIs) were used to calculate disproportionality. <jats:bold>Results:<\/jats:bold> We identified 33,488 COVID-19 patients and 2397 COVID-19 patients with DM. AKI was the most frequent adverse drug reaction (ADR) reported in this patient population. The primary suspected drugs related to AKI in more than half of the reports (75.60%, 127\/168) were four common anti-COVID-19 drugs (remdesivir, tocilizumab, hydroxychloroquine, and lopinavir\/ritonavir). Compared with other drugs in the same time window, remdesivir and lopinavir\/ritonavir were associated with an increased risk of AKI in all COVID-19 patients (ROR: 3.97, 95% CI: 3.51\u20134.50; ROR: 4.02, 95% CI: 3.11\u20135.19, respectively). In COVID-19 patients with DM, remdesivir was significantly associated with AKI (ROR: 5.65, 95% CI: 4.06\u20137.87); meanwhile, there was a new AKI signal associated with tocilizumab (ROR: 2.37, 95% CI: 1.19\u20134.72). After sensitivity analyses in COVID-19 patients with DM, consistent results for remdesivir were observed; however, the AKI signals for tocilizumab were unstable.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Our study confirmed the association of AKI with the usage of common anti-COVID-19 drugs (especially remdesivir and tocilizumab) in DM patients. These safety signals suggested more individualized treatments for COVID-19 patients with comorbidities. Cross-disciplinary collaborative is needed to improve current strategy of clinical treatment and develop new approaches to management.<\/jats:p>","DOI":"10.3389\/fphar.2022.833679","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T06:18:58Z","timestamp":1647497938000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Acute Kidney Injury and Drugs Prescribed for COVID-19 in Diabetes Patients: A Real-World Disproportionality Analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Yu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaping","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1080\/1061186x.2020.1797754","article-title":"Pharmacotherapy in COVID-19 Patients: A Review of ACE2-Raising Drugs and Their Clinical Safety","volume":"28","author":"Akhtar","year":"2020","journal-title":"J. Drug Target."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1016\/j.ekir.2020.07.035","article-title":"Acute Kidney Injury Associated with Lopinavir\/Ritonavir Combined Therapy in Patients with COVID-19","volume":"5","author":"Binois","year":"2020","journal-title":"Kidney Int. Rep."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1007\/s00125-020-05180-x","article-title":"Phenotypic Characteristics and Prognosis of Inpatients with COVID-19 and Diabetes: The Coronado Study","volume":"63","author":"Cariou","year":"2020","journal-title":"Diabetologia"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.kint.2021.02.015","article-title":"Kidney Disorders as Serious Adverse Drug Reactions of Remdesivir in Coronavirus Disease 2019: A Retrospective Case-Noncase Study","volume":"99","author":"Chouchana","year":"2021","journal-title":"Kidney Int."},{"key":"B5","doi-asserted-by":"publisher","first-page":"bnaa011","DOI":"10.1210\/endrev\/bnaa011","article-title":"Coronavirus Infections and Type 2 Diabetes-Shared Pathways with Therapeutic Implications","volume":"41","author":"Drucker","year":"2020","journal-title":"Endocr. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ijid.2020.06.093","article-title":"Case Report Study of the First Five COVID-19 Patients Treated with Remdesivir in France","volume":"98","author":"Dubert","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1002\/cpt.2145","article-title":"Remdesivir and Acute Renal Failure: A Potential Safety Signal from Disproportionality Analysis of the WHO Safety Database","volume":"109","author":"G\u00e9rard","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.dsx.2020.04.018","article-title":"Diabetes Mellitus Is Associated with Increased Mortality and Severity of Disease in COVID-19 Pneumonia - A Systematic Review, Meta-Analysis, and Meta-Regression","volume":"14","author":"Huang","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"B9","doi-asserted-by":"publisher","first-page":"108125","DOI":"10.1016\/j.diabres.2020.108125","article-title":"COVID-19 and Diabetes: Can DPP4 Inhibition Play a Role?","volume":"162","author":"Iacobellis","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"6109","DOI":"10.3390\/ijms22116109","article-title":"The Mechanism of Drug Nephrotoxicity and the Methods for Preventing Kidney Damage","volume":"22","author":"Kwiatkowska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41574-020-00435-4","article-title":"COVID-19 and Diabetes Mellitus: from Pathophysiology to Clinical Management","volume":"17","author":"Lim","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1159\/000510455","article-title":"Drug-Induced Hospital-Acquired Acute Kidney Injury in China: A Multicenter Cross-Sectional Survey","volume":"7","author":"Liu","year":"2021","journal-title":"Kidney Dis. (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2337\/dc20-2676","article-title":"Diabetes and Overweight\/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-Analysis","volume":"44","author":"Longmore","year":"2021","journal-title":"Diabetes Care"},{"key":"B14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and Strengths of the Disproportionality Analysis for Identification of Adverse Drug Reactions in a Pharmacovigilance Database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e03647","DOI":"10.1128\/mBio.03647-20","article-title":"Comorbidities in SARS-CoV-2 Patients: A Systematic Review and Meta-Analysis","volume":"12","author":"Ng","year":"2021","journal-title":"mBio"},{"key":"B16","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection Algorithms and Attentive Points of Safety Signal Using Spontaneous Reporting Systems as a Clinical Data Source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief Bioinform"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized with COVID-19 in the New York City Area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"B18","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s40264-021-01091-x","article-title":"Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase during 2020","volume":"44","author":"Rocca","year":"2021","journal-title":"Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e0249760","DOI":"10.1371\/journal.pone.0249760","article-title":"Therapy with Lopinavir\/Ritonavir and Hydroxychloroquine Is Associated with Acute Kidney Injury in COVID-19 Patients","volume":"16","author":"Schneider","year":"2021","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1080\/14740338.2021.1962846","article-title":"Assessment of Adverse Events Associated with Remdesivir Use for Coronavirus Disease 2019 Using Real-World Data","volume":"20","author":"Singh","year":"2021","journal-title":"Expert Opin. Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"B22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ijid.2020.03.017","article-title":"Prevalence of Comorbidities and its Effects in Patients Infected with SARS-CoV-2: A Systematic Review and Meta-Analysis","volume":"94","author":"Yang","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"B23","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.semnephrol.2020.09.001","article-title":"Acute Kidney Injury in COVID-19: The Chinese Experience","volume":"40","author":"Zheng","year":"2020","journal-title":"Semin. Nephrol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/s0140-6736(20)30566-3","article-title":"Clinical Course and Risk Factors for Mortality of Adult Inpatients with COVID-19 in Wuhan, China: A Retrospective Cohort Study","volume":"395","author":"Zhou","year":"2020","journal-title":"Lancet"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.833679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T06:19:00Z","timestamp":1647497940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.833679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":24,"alternative-id":["10.3389\/fphar.2022.833679"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.833679","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"article-number":"833679"}}